ASX Admission Market Release
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm Secures Key US Patent
- Paradigm Biopharmaceuticals Receives Ethics Approval
- Paradigm starts Clinical Trial
- Paradigm initiates second clinical trial site
- First Participant treated in Paradigms Clinical Trial
Later from Paradigm Biopharmaceuticals
- Shareholders Update
- Paradigm PPS nasal spray to treat Allergic Rhinitis
- Preliminary Final Report
- Paradigm PPS a potential in the treatment of viral arthritis
- Preclinical study underpins efficacy of Paradigms RhinosulR
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals